Learn more

DAE WOONG PHARMA

Overview
  • Total Patents
    840
  • GoodIP Patent Rank
    3,293
  • Filing trend
    ⇧ 60.0%
About

DAE WOONG PHARMA has a total of 840 patent applications. It increased the IP activity by 60.0%. Its first patent ever was published in 1983. It filed its patents most often in Republic of Korea, WIPO (World Intellectual Property Organization) and China. Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and biotechnology are SHANGHAI LONGWOOD BIOPHARMACEUTICALS CO LTD, ASANA BIOSCIENCES LLC and CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY SHIJIAZHUANG CO LTD.

Patent filings per year

Chart showing DAE WOONG PHARMAs patent filings per year from 1900 to 2020

Top inventors

# Name Total Patents
#1 Kim Ji Duck 90
#2 Kim In Woo 83
#3 Park Joon Seok 69
#4 Jun Sun Ah 65
#5 Lee Jun Hee 62
#6 Eom Deok Ki 50
#7 Han Mi Ryeong 49
#8 Lee Byung Goo 49
#9 Lee Chun Ho 49
#10 Choi Soo Jin 46

Latest patents

Publication Filing date Title
KR20210023710A Sustained release composition of niclosamide and antiviral uses thereof
WO2020175935A1 Albumin-bound composition including lrrd2 of slit3 protein for prevention or treatment of bone-related diseases
WO2020175931A1 Composition comprising albumin-coupled slit3 lrrd2 for prevention or treatment of muscle disease
WO2020175922A2 Pharmaceutical composition of single dosage form for treating or preventing hypertension and hyperlipidemia
WO2020060213A1 Method for producing 4-methoxy pyrrole derivative
KR20200033178A Manufacturing method for 4-methoxypyrrole derivatives
WO2020045941A1 Novel heterocyclic amine derivative and pharmaceutical composition comprising same
KR20200024111A Novel heterocyclicamine derivatives and pharmaceutical composition comprising the same
CA3109107A1 Preparation of intermediate useful for synthesis of sglt inhibitor
WO2020022847A1 Recombinant yeast strain having sterol productivity, preparation method therefor and use thereof
KR20200132001A A transdermal preparation comprising a high content of donepezil or a salt thereof
KR20200125061A Biomarkers for diagnosing chronic myeloid leukemia
KR20200118628A Container assembly
WO2020153507A1 Cover assembly and dual container comprising same
KR20200082006A Extended release formulation containing tofacitinib or pharmaceutically acceptable salts thereof as an active ingredient and the preparation method for the same
WO2019132562A1 Oxy-fluoropiperidine derivative as kinase inhibitor
WO2020111295A1 Safety cap for syringe and safety syringe comprising same
WO2020111296A1 Two-chamber type combined container-syringe
KR102037466B1 All-in-one spout to prevent contamination and container assembly comprising the same
KR20200017078A Long-acting Insulin Analog and Derivatives Thereof